Dutch pharma association pushes back on cost-control policies with a report highlighting the sector's broader economic value
The Dutch innovative pharmaceutical industry accounted for an estimated €8.5 billion in gross added value in 2024, according to a report by the Dutch Association for Innovative Medicines (VIG).
The report demonstrates the value of the sector as a strategic economic asset rather than just as a cost to the health system, in an effort to push back on policies that focus on cost control with deteriorating access to new medicines and vaccines.
ING healthcare economist Diederik Stadig described the VIG’s figure as “a good estimate”.
“The Netherlands has a dense, high-productivity life sciences cluster, combining pharma, biotech and manufacturing,” Stadig told Euractiv. “Given the sector’s capital intensity and export orientation, a multi‑billion euro value added contribution is very credible.”
